Seer, Inc. (NASDAQ:SEER – Get Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 191,696 shares, a decline of 34.8% from the May 31st total of 293,816 shares. Based on an average daily volume of 127,131 shares, the short-interest ratio is currently 1.5 days. Currently, 0.4% of the shares of the company are sold short.
Analysts Set New Price Targets
SEER has been the subject of a number of research reports. Canaccord Genuity Group assumed coverage on shares of Seer in a research note on Monday, May 4th. They set a “buy” rating and a $4.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research note on Tuesday, April 21st. Finally, TD Cowen raised Seer to a “strong-buy” rating in a report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $4.00.
Get Our Latest Stock Report on Seer
Institutional Trading of Seer
Seer Stock Performance
SEER opened at $1.62 on Friday. The firm’s 50 day simple moving average is $1.78 and its two-hundred day simple moving average is $1.83. The company has a market capitalization of $89.07 million, a PE ratio of -1.31 and a beta of 1.59. Seer has a 1-year low of $1.55 and a 1-year high of $2.41.
Seer (NASDAQ:SEER – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.30). Seer had a negative return on equity of 26.58% and a negative net margin of 464.78%.The firm had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $3.60 million.
Seer Company Profile
Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.
The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.
Featured Articles
- Five stocks we like better than Seer
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.
